GoodRx Holdings, Inc. Class A Common Stock (GDRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XFRA 
Is GoodRx (GDRX) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Compared to Estimates, GoodRx (GDRX) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago.
GoodRx Holdings, Inc. (GDRX) Reports Next Week: Wall Street Expects Earnings Growth
GoodRx (GDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform
GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
GoodRx: Great Value For Patient Investors (Upgrade)
GoodRx is a great small-cap value stock to buy amid the recent downturn. I'm upgrading the stock to a buy. GoodRx showcases strong adjusted EBITDA despite slower growth, making it an attractive target for private equity deals as public equities become less appealing. The company's new CEO is driving a wholesale change in business strategy, chasing relationships directly with pharmaceutical manufacturers.
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
GoodRx Holdings Inc. GDRX reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and consensus of $199.75 million.
GoodRx Holdings, Inc. (GDRX) Q4 2024 Earnings Call Transcript
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director, IR Wendy Barnes - CEO Chris McGinnis - CFO Conference Call Participants Lisa Gill - J.P. Morgan John Ransom - RJF Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jenny Cao - Truist Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Steven Valiquette - Mizuho Securities Jay Jin - Morgan Stanley George Hill - Deutsche Bank Allen Lutz - Bank of America Operator Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Fourth Quarter and Full Year 2024 Earnings Call.
Here's What Key Metrics Tell Us About GoodRx (GDRX) Q4 Earnings
While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GoodRx Holdings, Inc. (GDRX) Q4 Earnings Match Estimates
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago.
Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics
Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
GoodRx CFO Karsten Voermann to Resign for Personal Reasons
GoodRx Holdings disclosed Monday (Jan. 13) that its chief financial officer, Karsten Voermann, submitted his resignation Tuesday (Jan. 7), effective Friday (Jan. 16). The company attributed the resignation to “personal reasons” in a Monday filing with the Securities and Exchange Commission.
